221 related articles for article (PubMed ID: 36528759)
1. Incidence of and risk factors for non-hematologic toxicity with combined radiotherapy and CDK4/6 inhibitors in metastatic breast cancer using dose-volume parameters analysis: a multicenter cohort study.
Kawamoto T; Shikama N; Imano N; Kubota H; Kosugi T; Sekii S; Harada H; Yamada K; Naoi Y; Miyazawa K; Hirano Y; Wada Y; Tonari A; Saito T; Uchida N; Araki N; Nakamura N
Breast Cancer; 2023 Mar; 30(2):282-292. PubMed ID: 36528759
[TBL] [Abstract][Full Text] [Related]
2. Safety of cyclin-dependent kinase4/6 inhibitor combined with palliative radiotherapy in patients with metastatic breast cancer.
Kim KN; Shah P; Clark A; Freedman GM; Dastgheyb S; Barsky AR; Dreyfuss AD; Taunk NK
Breast; 2021 Dec; 60():163-167. PubMed ID: 34653725
[TBL] [Abstract][Full Text] [Related]
3. Outcomes and toxicity of concurrent CDK4/6 inhibitor and locoregional radiotherapy for patients with de novo metastatic breast cancer.
Beddok A; Mouren V; Cottu P; Laki F; Fourquet A; Kirova Y
Int J Cancer; 2023 Oct; 153(7):1386-1396. PubMed ID: 37381597
[TBL] [Abstract][Full Text] [Related]
4. Safety and feasibility of CDK4/6 inhibitors treatment combined with radiotherapy in patients with HR-positive/HER2-negative breast cancer. A systematic review and meta-analysis.
Kubeczko M; Jarząb M; Gabryś D; Krzywon A; Cortez AJ; Xu AJ
Radiother Oncol; 2023 Oct; 187():109839. PubMed ID: 37536378
[TBL] [Abstract][Full Text] [Related]
5. Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer.
Visani L; Livi L; Ratosa I; Orazem M; Ribnikar D; Saieva C; Becherini C; Salvestrini V; Scoccimarro E; Valzano M; Cerbai C; Desideri I; Bernini M; Orzalesi L; Nori J; Bianchi S; Morandi A; Meattini I
Radiother Oncol; 2022 Dec; 177():40-45. PubMed ID: 36349599
[TBL] [Abstract][Full Text] [Related]
6. Radiation Therapy With Cyclin-Dependent Kinase 4/6 Inhibitors: A Multi-institutional Safety and Toxicity Study.
Al-Rashdan A; Quirk S; Roumeliotis M; Abedin T; Amaro CP; Barbera L; Lupichuk S; Cao JQ
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(3):399-408. PubMed ID: 35870712
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-Dependent Kinase 4/6 Inhibitors Combined With Radiotherapy for Patients With Metastatic Breast Cancer.
Ratosa I; Orazem M; Scoccimarro E; Steinacher M; Dominici L; Aquilano M; Cerbai C; Desideri I; Ribnikar D; Marinko T; Livi L; Meattini I
Clin Breast Cancer; 2020 Dec; 20(6):495-502. PubMed ID: 32622736
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer: A Review.
O'Sullivan CC; Clarke R; Goetz MP; Robertson J
JAMA Oncol; 2023 Sep; 9(9):1273-1282. PubMed ID: 37382948
[TBL] [Abstract][Full Text] [Related]
9. Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis.
Becherini C; Visani L; Caini S; Bhattacharya IS; Kirby AM; Nader Marta G; Morgan G; Salvestrini V; Coles CE; Cortes J; Curigliano G; de Azambuja E; Harbeck N; Isacke CM; Kaidar-Person O; Marangoni E; Offersen B; Rugo HS; Morandi A; Lambertini M; Poortmans P; Livi L; Meattini I
Cancer Treat Rev; 2023 Sep; 119():102586. PubMed ID: 37336117
[TBL] [Abstract][Full Text] [Related]
10. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ
Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562
[TBL] [Abstract][Full Text] [Related]
11. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
[TBL] [Abstract][Full Text] [Related]
12. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
Schneeweiss A; Ettl J; Lüftner D; Beckmann MW; Belleville E; Fasching PA; Fehm TN; Geberth M; Häberle L; Hadji P; Hartkopf AD; Hielscher C; Huober J; Ruckhäberle E; Janni W; Kolberg HC; Kurbacher CM; Klein E; Lux MP; Müller V; Nabieva N; Overkamp F; Tesch H; Laakmann E; Taran FA; Seitz J; Thomssen C; Untch M; Wimberger P; Wuerstlein R; Volz B; Wallwiener D; Wallwiener M; Brucker SY
Breast; 2020 Dec; 54():88-95. PubMed ID: 32956934
[TBL] [Abstract][Full Text] [Related]
13. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
14. Racial disparities in neutrophil counts among patients with metastatic breast cancer during treatment with CDK4/6 inhibitors.
Schreier A; Munoz-Arcos L; Alvarez A; Sparano JA; Anampa JD
Breast Cancer Res Treat; 2022 Jul; 194(2):337-351. PubMed ID: 35633421
[TBL] [Abstract][Full Text] [Related]
15. Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data.
Martin JM; Handorf EA; Montero AJ; Goldstein LJ
Oncologist; 2022 Jun; 27(6):441-446. PubMed ID: 35552450
[TBL] [Abstract][Full Text] [Related]
16. Safety and Feasibility of Radiation Therapy Combined with CDK 4/6 Inhibitors in the Management of Advanced Breast Cancer.
Kubeczko M; Gabryś D; Gawkowska M; Polakiewicz-Gilowska A; Cortez AJ; Krzywon A; Woźniak G; Latusek T; Leśniak A; Świderska K; Mianowska-Malec M; Łanoszka B; Chomik K; Gajek M; Michalik A; Nowicka E; Tarnawski R; Rutkowski T; Jarząb M
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765648
[TBL] [Abstract][Full Text] [Related]
17. Real-world treatment patterns of subsequent therapy after palbociclib in patients with advanced breast cancer in Japan.
Sawaki M; Muramatsu Y; Togo K; Iwata H
Breast; 2023 Aug; 70():1-7. PubMed ID: 37267715
[TBL] [Abstract][Full Text] [Related]
18. Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.
Choong GM; Liddell S; Ferre RAL; O'Sullivan CC; Ruddy KJ; Haddad TC; Hobday TJ; Peethambaram PP; Liu MC; Goetz MP; Giridhar KV
Breast Cancer Res Treat; 2022 Nov; 196(1):229-237. PubMed ID: 36045271
[TBL] [Abstract][Full Text] [Related]
19. Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review.
Zhao M; Hanson KA; Zhang Y; Zhou A; Cha-Silva AS
Target Oncol; 2023 May; 18(3):327-358. PubMed ID: 37074594
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Kim SB
Cancer Res Treat; 2022 Apr; 54(2):469-477. PubMed ID: 34176251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
